All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @kristinastout on TikTok · 58s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @kristinastout's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hi, I'm Christina. I'm a nurse practitioner and let's talk about a peptide that I feel like has become
  2. 0:05Increasingly popular lately. So that is my Delta sleep inducing peptide DSIP
  3. 0:10That increases your delta waves to help you fall asleep faster and stay asleep for longer
  4. 0:15So if you are one of these people who wake up at 3 a.m. In the morning and you just cannot go back to sleep
  5. 0:20This is the peptide for you. It has also been shown to help some people with cortisol
  6. 0:26Mood and stress levels so we all know that effects sleep so it can help with sleep in that way as well
  7. 0:32My cost for this one is 275 for a five week supply
  8. 0:36It comes directly from a 503 a compounding pharmacy ship directly to you
  9. 0:42reconstituted ready to go with alcohol wipes and syringes all of my
  10. 0:46Pricing is straightforward includes consultation visits and everything that you need if you have any more questions
  11. 0:51Let me know and if you want to book a consultation
  12. 0:54You can go to harmony wellness clinic calm. We are now in 23 states

@kristinastout's DSIP peptide claims need more evidence

Kristina | Nurse Practitioner

TikTok creator

29.7K viewsWatch on TikTok

Quick answer

The creator promotes DSIP as a sleep aid that increases delta-wave activity and may modulate cortisol, marketing it at $275 for a five-week supply from a 503A compounding pharmacy across 23 states. Human clinical evidence for DSIP's sleep-promoting effects is limited primarily to small, dated trials, and no FDA-approved DSIP product exists. Patients with chronic sleep maintenance issues should be assessed for underlying causes before pursuing compounded peptide therapy with unestablished efficacy in human populations.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 4 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @kristinastout's DSIP peptide claims need more evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@kristinastout's DSIP peptide claims need more evidence is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@kristinastout's DSIP peptide claims need more evidence" from Kristina | Nurse Practitioner. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator promotes DSIP as a sleep aid that increases delta-wave activity and may modulate cortisol, marketing it at $275 for a five-week supply from a 503A compounding pharmacy across 23 states.

The reason this review is not generic is the source wording and the canonical claim label "peptides delta sleep inducing peptide dsip harmony wellness clinic." In this clip, the useful excerpt is: "Hi, I'm Christina." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Emerging pharmacotherapies for obesity: A systematic review (2025), Glucagon-like receptor agonists and next-generation incretin-based medications (2026), and Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A 1990 human volunteer study (Steiger et al.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator promotes DSIP as a sleep aid that increases delta-wave activity and may modulate cortisol, marketing it at $275 for a five-week supply from a 503A compounding pharmacy across 23 states.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator promotes DSIP as a sleep aid that increases delta-wave activity and may modulate cortisol, marketing it at $275 for a five-week supply from a 503A compounding pharmacy across 23 states. Human clinical evidence for DSIP's sleep-promoting effects is limited primarily to small, dated trials, and no FDA-approved DSIP product exists. Patients with chronic sleep maintenance issues should be assessed for underlying causes before pursuing compounded peptide therapy with unestablished efficacy in human populations.
  • DSIP was first isolated in 1977 (Monnier et al.) and most sleep-promoting data comes from animal studies, not human clinical trials.
  • A 1990 human volunteer study (Steiger et al., Journal of Sleep Research) found no significant sleep effect from DSIP administration, directly contradicting the video's core claim.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • DSIP was first isolated in 1977 (Monnier et al.) and most sleep-promoting data comes from animal studies, not human clinical trials.
  • A 1990 human volunteer study (Steiger et al., Journal of Sleep Research) found no significant sleep effect from DSIP administration, directly contradicting the video's core claim.
  • DSIP has a very short plasma half-life, raising unresolved questions about whether subcutaneous dosing produces meaningful brain activity in humans.
  • CBT-I (cognitive behavioral therapy for insomnia) has Level 1 human evidence for sleep maintenance problems (Trauer et al., 2015, Annals of Internal Medicine) and should be considered before unproven peptide therapy.
  • DSIP is not FDA-approved for any indication and exists in a regulatory gray zone; compounded versions are not equivalent to any approved drug product.
  • The cortisol-sleep connection the creator mentions is biologically reasonable, but no human trial has established DSIP as an effective cortisol modulator at therapeutic doses.
  • At $275 for five weeks, patients should ask their provider for the specific evidence base and discuss what measurable outcomes would indicate the therapy is or is not working.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @kristinastout actually say?

She made three core claims: DSIP "increases your delta waves to help you fall asleep faster and stay asleep for longer," it can help people who "wake up at 3 a.m. and cannot go back to sleep," and it has shown benefit for "cortisol, mood and stress levels." She also disclosed her pricing and sourcing from a 503A compounding pharmacy.

To her credit, she did not promise a cure, she disclosed her credentials as a nurse practitioner, and she named her clinic. That is more transparency than most peptide TikToks offer. The problem is not what she disclosed, it is what the science actually says about DSIP, which is considerably messier than a 60-second video can capture.

Does the science back this up?

Partially, and with significant caveats. The evidence for DSIP in humans is thin, dated, and largely inconclusive. Most people citing DSIP's sleep benefits are drawing on animal studies and a small body of human research from the 1980s.

DSIP was first isolated in 1977 by Monnier and colleagues from rabbit cerebral venous blood during slow-wave sleep. Early animal studies did show increases in delta-wave activity after administration. However, a 1984 review by Iyer and colleagues in Neuroscience and Biobehavioral Reviews noted that DSIP's sleep-promoting effects were inconsistent across species and experimental conditions. The peptide also has a very short half-life in plasma, which raises serious questions about whether subcutaneous injection produces meaningful central nervous system activity at all. A 1990 study by Steiger and colleagues in Journal of Sleep Research found no significant sleep-promoting effect in healthy volunteers. The cortisol angle has some biological plausibility, with some rodent data suggesting DSIP modulates stress hormone release, but again, robust human trials are absent.

What did they get wrong (or right)?

The claim that DSIP "increases your delta waves" is technically drawn from real research but is being presented with more confidence than the data supports. The human evidence for this specific effect is weak. Saying this is the peptide for people who "wake up at 3 a.m." is a marketing statement, not a clinical recommendation, and it implies a specificity of action that no published trial has demonstrated in humans.

What she got right: disclosing sourcing from a 503A pharmacy is relevant and appropriate. Compounded peptides are not FDA-approved drugs, and knowing the pharmacy type matters for safety. She also correctly framed cortisol and stress as related to sleep quality rather than claiming DSIP directly fixes a sleep disorder, which is a meaningful distinction. The pricing disclosure is also a positive, though $275 for a five-week supply of a peptide with limited human evidence is a figure patients should weigh carefully.

  • Right: credentials disclosed, pharmacy sourcing named, cortisol-sleep connection is biologically reasonable
  • Wrong: overstates certainty of delta-wave effects in humans, implies specificity of use case without clinical trial support
  • Unclear: whether reconstituted compounded DSIP maintains stability and bioavailability is not addressed

What should you actually know?

DSIP is not FDA-approved for any indication. It is not a scheduled substance in the United States, but it exists in a regulatory gray zone. Anyone considering it should understand that the human clinical evidence is genuinely sparse, most of it is decades old, and the peptide's pharmacokinetics remain poorly characterized in living humans outside laboratory settings.

Sleep problems that cause someone to wake at 3 a.m. have a range of causes, including sleep apnea, cortisol dysregulation, anxiety, and hormonal shifts, and none of those are reliably addressed by a peptide with a questionable half-life and inconsistent research results. Before spending $275, a patient would be better served by a sleep study, cortisol testing, and a conversation about CBT-I, which has actual Level 1 evidence behind it (Trauer et al., 2015, Annals of Internal Medicine). DSIP might eventually prove useful as the science matures. Right now, the gap between the confidence of this video and the actual evidence is wide enough to matter.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kristina | Nurse Practitioner · TikTok creator

29.7K views on this video

Delta sleep inducing peptide DSIP @Harmony Wellness Clinic #nursesoftiktok #nurse #fit #healing #peptide

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about dsip was first?

DSIP was first isolated in 1977 (Monnier et al.) and most sleep-promoting data comes from animal studies, not human clinical trials.

What does the video say about a 1990 human volunteer study (steiger et al., journal of?

A 1990 human volunteer study (Steiger et al., Journal of Sleep Research) found no significant sleep effect from DSIP administration, directly contradicting the video's core claim.

What does the video say about dsip has a very short plasma half-life, raising unresolved questions?

DSIP has a very short plasma half-life, raising unresolved questions about whether subcutaneous dosing produces meaningful brain activity in humans.

What does the video say about cbt-i (cognitive behavioral therapy for insomnia) has level 1 human?

CBT-I (cognitive behavioral therapy for insomnia) has Level 1 human evidence for sleep maintenance problems (Trauer et al., 2015, Annals of Internal Medicine) and should be considered before unproven peptide therapy.

What does the video say about dsip?

DSIP is not FDA-approved for any indication and exists in a regulatory gray zone; compounded versions are not equivalent to any approved drug product.

What does the video say about the cortisol-sleep connection the creator mentions?

The cortisol-sleep connection the creator mentions is biologically reasonable, but no human trial has established DSIP as an effective cortisol modulator at therapeutic doses.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kristina | Nurse Practitioner, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.